Form 4: Theravance Biopharma CEO Sells Shares to Cover Tax Obligations

Theravance Biopharma's CEO, Rick E. Winningham, sold 15,997 shares to cover tax obligations related to vesting restricted stock units.

Summary

• Rick E. Winningham, CEO of Theravance Biopharma, sold 15,997 ordinary shares on November 20, 2024.
• The shares were sold at a price of $9.97 per share.
• This transaction was to cover tax obligations arising from the vesting of previously granted restricted stock units.
• The sale was not an open market transaction but a share withholding transaction with the issuer.
• Following the transaction, Winningham directly owns 1,811,095 ordinary shares.
• He also indirectly owns 3,900 shares as custodian and 92,567 shares through a trust.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Executive share sales to cover tax obligations are a common practice across the pharmaceutical and biotech industries.
• Many companies use restricted stock units as part of executive compensation packages, leading to similar tax-related sales.
• The scale of this transaction is relatively small compared to the total holdings of the CEO, which is typical for tax-related sales.

Stakeholder Impact

• The share sale is unlikely to have a significant impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Theravance Biopharma, Rick E. Winningham, share sale, insider trading, tax obligations, restricted stock units, Form 4